| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TOR1AIP1 |
| Uniprot No | Q5JTV8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-583aa |
| 氨基酸序列 | MAGDGRRAEAVREGWGVYVTPRAPIREGRGRLAPQNGGSSDAPAYRTPPSRQGRREVRFSDEPPEVYGDFEPLVAKERSPVGKRTRLEEFRSDSAKEEVRESAYYLRSRQRRQPRPQETEEMKTRRTTRLQQQHSEQPPLQPSPVMTRRGLRDSHSSEEDEASSQTDLSQTISKKTVRSIQEAPVSEDLVIRLRRPPLRYPRYEATSVQQKVNFSEEGETEEDDQDSSHSSVTTVKARSRDSDESGDKTTRSSSQYIESFWQSSQSQNFTAHDKQPSVLSSGYQKTPQEWAPQTARIRTRMQNDSILKSELGNQSPSTSSRQVTGQPQNASFVKRNRWWLLPLIAALASGSFWFFSTPEVETTAVQEFQNQMNQLKNKYQGQDEKLWKRSQTFLEKHLNSSHPRSQPAILLLTAARDAEEALRCLSEQIADAYSSFRSVRAIRIDGTDKATQDSDTVKLEVDQELSNGFKNGQNAAVVHRFESFPAGSTLIFYKYCDHENAAFKDVALVLTVLLEEETLGTSLGLKEVEEKVRDFLKVKFTNSNTPNSYNHMDPDKLNGLWSRISHLVLPVQPENALKRGICL |
| 预测分子量 | 66,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TOR1AIP1重组蛋白的模拟参考文献示例(建议通过PubMed或Google Scholar核实具体文献)：
---
1. **文献名称**：*"Recombinant TOR1AIP1 Expression and Its Role in Nuclear Envelope Integrity"*
**作者**：Chen et al., 2018
**摘要**：研究报道了在大肠杆菌中成功表达并纯化重组TOR1AIP1蛋白，实验证实其通过与核膜蛋白LAP1相互作用维持核膜稳定性，为研究核纤层相关疾病提供了工具。
2. **文献名称**：*"Functional Characterization of TOR1AIP1 Mutants Using Recombinant Protein Assays"*
**作者**：Miyamoto et al., 2020
**摘要**：通过重组TOR1AIP1蛋白体外实验，揭示特定突变导致蛋白与核膜结合能力丧失，解释了部分先天性肌营养不良患者的致病机制。
3. **文献名称**：*"Structural Insights into TOR1AIP1-LULL1 Complex Formation"**
**作者**：Gupta et al., 2019
**摘要**：利用重组TOR1AIP1蛋白进行结晶学研究，解析其与LULL1蛋白的相互作用结构域，为靶向治疗开发提供分子基础。
4. **文献名称**：*"Recombinant TOR1AIP1 Rescues Cellular Phenotypes in Disease Models"*
**作者**：Park et al., 2021
**摘要**：在患者来源的成纤维细胞中导入重组TOR1AIP1蛋白，成功修复核膜异常并改善细胞功能，验证了其潜在治疗价值。
---
**注意**：以上为基于TOR1AIP1常见研究方向的模拟摘要，实际文献需通过学术数据库检索(关键词：TOR1AIP1 recombinant, nuclear envelope, muscular dystrophy)。
**Background of TOR1AIP1 Recombinant Protein**
TOR1AIP1 (TOR1A Interacting Protein 1), also known as LAP1 (lamina-associated polypeptide 1), is a nuclear envelope protein encoded by the *TOR1AIP1* gene. It interacts with Torsin-1A (TOR1A), an ATPase implicated in neurological disorders such as early-onset dystonia. TOR1AIP1 exists in multiple isoforms (e.g., LAP1B, LAP1C) generated by alternative splicing, with LAP1B being the predominant form. Structurally, it contains a nucleoplasmic N-terminal domain, a transmembrane segment, and a luminal C-terminal region that binds Torsin-1A within the endoplasmic reticulum (ER) or perinuclear space.
Functionally, TOR1AIP1 plays critical roles in maintaining nuclear envelope integrity, regulating nuclear-cytoskeletal interactions, and influencing chromatin organization. It is involved in cellular processes like mitosis, mechanotransduction, and ER stress response. Mutations in *TOR1AIP1* are linked to severe human pathologies, including autosomal recessive muscular dystrophy, cardiomyopathy, and progressive dystonia, highlighting its importance in muscle and neuronal homeostasis.
Recombinant TOR1AIP1 protein is engineered for in vitro studies to dissect its molecular interactions, particularly with Torsin-1A and other nuclear envelope components. It aids in exploring disease mechanisms, such as how pathogenic mutations disrupt nuclear membrane dynamics or ER-associated degradation (ERAD). Additionally, it serves as a tool for drug screening to identify compounds that modulate Torsin-1A activity or restore nuclear envelope defects. Research utilizing recombinant TOR1AIP1 contributes to understanding cellular architecture and developing therapies for TOR1AIP1-associated disorders.
×
